ACE-031 Protocol: Complete Cycling & Dosing Guide
Overview
ACE-031 is a recombinant fusion protein that functions as a decoy receptor for myostatin and related TGF-beta family ligands. Unlike selective myostatin antibodies, ACE-031 simultaneously inhibits multiple growth-suppressing signals (myostatin, activin A, GDF-11), making it a broader and more potent anabolic tool. It works by blocking ActRIIB signaling pathways, disinhibiting Akt/mTOR cascade activation while suppressing SMAD2/3 phosphorylation—the net result being accelerated muscle protein synthesis, satellite cell activation, and increased muscle fiber hypertrophy and hyperplasia.
Key Point: ACE-031 is a slow-acting, long-duration compound. A single injection produces measurable lean mass increases over 4 weeks, with peak effects often observed at 28–35 days post-injection. This long pharmacokinetic profile eliminates the need for frequent dosing and simplifies protocol design.
Regulatory Status: ACE-031 is not approved for any indication by any regulatory authority. Phase 2 clinical trials were halted early due to dose-dependent vascular side effects (cutaneous telangiectasias, epistaxis, gingival bleeding). Use outside supervised clinical research is unapproved and legally restricted in most jurisdictions. This guide is educational only.
Standard Protocol
Baseline Dosing Framework
The established clinical dosing range is 1–3 mg/kg administered once every 4 weeks. This wide range reflects the dose-response relationship observed in human trials, where 3 mg/kg produced measurable lean mass gains in healthy women, while lower doses have been used in muscular dystrophy populations.
Standard dosing recommendations:
- Lean Mass Building (Primary Goal): 2–3 mg/kg every 4 weeks
- Muscle Gain with Reduced Side Effect Risk: 1.5–2 mg/kg every 4 weeks
- Conservative/First-Use Protocol: 1 mg/kg every 4 weeks, escalate after tolerance assessment
Calculating Your Dose:
For a 90 kg individual:
- 1 mg/kg = 90 mg per injection
- 1.5 mg/kg = 135 mg per injection
- 2 mg/kg = 180 mg per injection
- 3 mg/kg = 270 mg per injection
Injection Frequency and Timing
ACE-031's long half-life and sustained effect profile mean that once-every-4-weeks dosing is standard. Do not administer more frequently than every 28 days; doing so significantly elevates vascular side effect risk without additional anabolic benefit.
Why 4 weeks? Peak lean mass responses occur around day 28–35 post-injection. A 4-week interval allows the previous dose to reach its plateau effect window, then a new dose is administered to sustain elevation.
Goal-Specific Protocols
Protocol A: Lean Mass Maximization (8–12 Week Cycle)
Objective: Maximum muscle and lean body mass gain with acceptance of moderate side effect risk.
Dosing Schedule:
- Week 0 (Day 0): 2.5–3 mg/kg (single injection)
- Week 4 (Day 28): 2.5–3 mg/kg (second injection)
- Week 8 (Day 56): 2.5–3 mg/kg (third injection)
- Week 12 (Day 84): End cycle. Do not inject.
Rationale: Three consecutive injections produce cumulative lean mass responses. The peak effects from the first dose are still present when the second is administered, creating sustained elevation of ActRIIB inhibition. By week 12, discontinue and allow clearance.
Expected Lean Mass Gain: 3–5% over 12 weeks (conservative estimate based on clinical data showing 3.3% at day 29 with single dose).
Side Effect Monitoring: Expect increased telangiectasias (small dilated blood vessels on skin), possible epistaxis (nosebleeds), and gingival bleeding at higher doses. Daily nasal saline rinses and careful oral hygiene reduce bleeding risk.
Protocol B: Moderate Gain with Safety Focus (12 Week Cycle)
Objective: Steady muscle gains while minimizing vascular side effects.
Dosing Schedule:
- Week 0 (Day 0): 1.5 mg/kg (single injection)
- Week 4 (Day 28): 1.5 mg/kg (second injection)
- Week 8 (Day 56): 1.5 mg/kg (third injection)
- Week 12 (Day 84): End cycle.
Rationale: Lower dose reduces telangiectasia incidence while maintaining anabolic stimulus. Clinical evidence supports 3 mg/kg for measurable response; 1.5 mg/kg is approximately half the maximum and should produce moderate but meaningful gains.
Expected Lean Mass Gain: 1.5–2.5% over 12 weeks.
Side Effect Profile: Minimal to mild. Most users report no vascular symptoms at this dose level. Injection site erythema and mild pain are possible but transient.
Protocol C: Extended Low-Dose Maintenance (16 Week Cycle)
Objective: Sustained muscle building with minimal downtime between cycles.
Dosing Schedule:
- Week 0: 1 mg/kg
- Week 4: 1 mg/kg
- Week 8: 1 mg/kg
- Week 12: 1 mg/kg
- Week 16: End cycle, 8-week washout before restarting
Rationale: Single 1 mg/kg doses spaced 4 weeks apart provide baseline myostatin inhibition without accumulating vascular stress. Best for long-term sustainable use.
Expected Lean Mass Gain: 1–2% over 16 weeks.
Side Effect Profile: Minimal across all parameters.
How to Administer: Step-by-Step
Pre-Injection Preparation
1. Reconstitution (if using lyophilized powder):
- Remove vial from storage (2–8°C, or as specified by supplier).
- Swab rubber septum with alcohol pad and allow to dry (30 seconds).
- Draw sterile bacteriostatic water or 0.9% saline (volume = concentration label specification).
- Inject slowly into vial at an angle (do not create pressure).
- Allow 2–3 minutes for powder to fully dissolve; gently roll vial (do not shake vigorously).
- Visually inspect: solution should be clear. Do not use if cloudy or discolored.
2. Dose Withdrawal:
- Using a new sterile syringe and 25–27 gauge needle, draw calculated dose volume.
- Expel air from syringe.
- Store reconstituted vial at 2–8°C; use within 14 days.
3. Injection Site Selection:
- Preferred sites: anterior thigh (quadriceps), abdomen (2+ inches from navel), or outer upper arm.
- Rotate injection sites with each dose to minimize local irritation.
- Avoid areas with active inflammation, scars, or lipohypertrophy.
Injection Technique
1. Skin Preparation:
- Clean injection site with alcohol pad in circular motions (outward from center).
- Allow 30 seconds to air-dry.
2. Needle Insertion:
- Pinch skin at injection site to create a lifted fold.
- Insert needle at 45–90 degree angle (45° for subcutaneous, 90° for intramuscular if protocol specifies).
- Advance needle until full depth is achieved.
- Release skin fold.
3. Injection:
- Slowly inject contents over 5–10 seconds.
- Withdraw needle and immediately apply gentle pressure with alcohol pad.
- Do not massage the injection site immediately after (allow 30 seconds, then gentle pressure only).
4. Post-Injection:
- Small erythema and mild swelling are normal; resolve within 24 hours.
- Apply ice pack for 5 minutes if significant swelling occurs.
- Monitor for signs of infection (increasing warmth, hardness, pus) over 48 hours; seek medical attention if present.
Storage and Stability
- Lyophilized Powder: Store at 2–8°C in original packaging, protected from light. Stable for the manufacturer's specified duration (typically 2–3 years).
- Reconstituted Solution: Once mixed, store at 2–8°C. Use within 14 days to minimize bacterial contamination risk and degradation.
- Do Not Freeze: Freezing can denature the protein and reduce potency.
- Do Not Shake Vigorously: Gentle rolling during reconstitution only.